Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808392 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRRAB9A | |
| SCHEMBL2435372 | 0.90 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL2432113 | 0.90 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL2432163 | 0.90 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL2432196 | 0.90 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL2434335 | 0.88 | SMN1; SMN2 (0.38) | ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL3569177 | 0.88 | SMN1; SMN2 (0.38) | ALDH1A1MEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL71925 | 0.80 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2ATSHRRAB9A | |
| SCHEMBL28516288 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRPOLB | |
| SCHEMBL2434805 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2ATSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-7345179-B2 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | DAICHI PAHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1698621-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | ALDH18A1, PLAAT4, ACSL4 | ALDH1A1 110/4885MEN1 3920/4885KMT2A 647/4885 |
| US-20070149607-A1 | Method for producing pyrrolidine derivative | ALDH18A1, PLAAT4, ACSL4 | ALDH1A1 110/4885MEN1 3920/4885KMT2A 647/4885 |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | ALDH1A1 139/4885MEN1 2854/4885KMT2A 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.